MA56541A - Plateformes, compositions et méthodes d'administration de composés thérapeutiques - Google Patents

Plateformes, compositions et méthodes d'administration de composés thérapeutiques

Info

Publication number
MA56541A
MA56541A MA056541A MA56541A MA56541A MA 56541 A MA56541 A MA 56541A MA 056541 A MA056541 A MA 056541A MA 56541 A MA56541 A MA 56541A MA 56541 A MA56541 A MA 56541A
Authority
MA
Morocco
Prior art keywords
platforms
compositions
methods
therapeutic compounds
delivering therapeutic
Prior art date
Application number
MA056541A
Other languages
English (en)
Inventor
Milad Riazifar
Todd Schurr
Charles Cameron Taylor
Original Assignee
Entelexo Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entelexo Biotherapeutics Inc filed Critical Entelexo Biotherapeutics Inc
Publication of MA56541A publication Critical patent/MA56541A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA056541A 2019-06-21 2020-06-19 Plateformes, compositions et méthodes d'administration de composés thérapeutiques MA56541A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962864566P 2019-06-21 2019-06-21
US201962875001P 2019-07-17 2019-07-17

Publications (1)

Publication Number Publication Date
MA56541A true MA56541A (fr) 2022-04-27

Family

ID=74037053

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056541A MA56541A (fr) 2019-06-21 2020-06-19 Plateformes, compositions et méthodes d'administration de composés thérapeutiques

Country Status (9)

Country Link
US (3) US20220112264A1 (fr)
EP (1) EP3986429A4 (fr)
JP (2) JP2022537807A (fr)
CN (1) CN114269360A (fr)
AU (1) AU2020298314A1 (fr)
CA (1) CA3144267A1 (fr)
IL (1) IL289114A (fr)
MA (1) MA56541A (fr)
WO (1) WO2020257710A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102771126B1 (ko) 2019-04-19 2025-02-20 후지필름 가부시키가이샤 세포 외 소포의 보존 안정화제 및 보존 안정화 방법
EP3986429A4 (fr) 2019-06-21 2023-07-19 Entelexo Biotherapeutics Inc. Plateformes, compositions et méthodes d'administration de composés thérapeutiques
CA3169228A1 (fr) 2020-02-05 2021-08-12 Diadem Biotherapeutics Inc. Synapses artificielles
CN115176138B (zh) 2020-02-24 2026-04-28 康宁股份有限公司 包含具有尼龙-6和染料的纳米颗粒的校准装置
EP4171596A1 (fr) 2020-06-24 2023-05-03 Chameleon Biosciences, Inc. Vésicules extracellulaires à modulateurs immuns
CN115776893A (zh) * 2020-07-09 2023-03-10 Exo生物制剂公司 结合蛋白质的细胞外囊泡的制造方法
WO2022133301A1 (fr) * 2020-12-18 2022-06-23 Entelexo Biotherapeutics, Inc. Plateformes, compositions et méthodes pour administration thérapeutique
EP4023231A1 (fr) * 2020-12-29 2022-07-06 Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana Vésicules extracellulaires dérivées de cellules stromales mésenchymateuses génétiquement modifiées pour la surexpression hif-1a et htert
CN112575005A (zh) * 2021-01-04 2021-03-30 昆明理工大学 一种提高烟草重金属镉胁迫抗性和降低镉富集的方法
US20220218755A1 (en) * 2021-01-11 2022-07-14 United Therapeutics Corporation Extracellular vesicles and their uses
EP4134088A4 (fr) * 2021-02-22 2023-12-20 Rohto Pharmaceutical Co., Ltd. Agent prophylactique et/ou thérapeutique pour le diabète
JP2024519945A (ja) * 2021-05-20 2024-05-21 アチェロイス バイオファーマ，インク． 免疫チェックポイント多価粒子の組成物、および使用方法
CN113521101A (zh) * 2021-05-20 2021-10-22 广州医科大学附属第一医院（广州呼吸中心） 干细胞来源的外泌体在制备治疗慢性阻塞性肺疾病药物中的应用
CN113769106A (zh) * 2021-08-13 2021-12-10 深圳湾实验室 用于肿瘤免疫治疗的融合细胞膜纳米囊泡、其制备方法及应用
WO2023076418A2 (fr) * 2021-10-26 2023-05-04 Entelexo Biotherapeutics, Inc. Plates-formes, compositions et méthodes d'administration thérapeutique
CN116218780A (zh) * 2021-12-03 2023-06-06 洪明奇 外泌体的生产及其用途
CN114107253B (zh) * 2021-12-17 2024-03-15 复旦大学附属华山医院 一种利用工程细胞进行基因编辑的系统及方法
WO2024000263A1 (fr) * 2022-06-29 2024-01-04 Beijing Thera Bioscience Co., Ltd. Procédés de fabrication et d'utilisation de vésicules extracellulaires
TWI895950B (zh) * 2023-01-30 2025-09-01 中國醫藥大學 外泌體、其製備方法、其用途以及醫藥組合物
JP7730003B2 (ja) * 2023-02-10 2025-08-27 中国▲医▼薬大学 細胞外小胞／エクソソーム保存溶液及びその混合溶液
CN118526597A (zh) * 2023-02-23 2024-08-23 厦门大学 Lrrk2抑制剂在抗肿瘤中的应用
KR102929157B1 (ko) 2023-03-08 2026-02-23 차이나 메디칼 유니버시티 엑소좀의 생산 및 이의 용도
EP4692323A4 (fr) * 2023-09-27 2026-04-01 Meis Tech Co Ltd Procédé de production d'un liquide contenant des exosomes dérivé de cellules souches mésenchymateuses et produit pharmaceutique contenant un liquide contenant des exosomes
CN117024557B (zh) * 2023-10-10 2024-01-30 天津外泌体科技有限公司 14-3-3蛋白theta异构体作为细胞外囊泡支架蛋白的应用和细胞外囊泡
WO2025101988A1 (fr) * 2023-11-09 2025-05-15 Nutech Ventures Petites vésicules extracellulaires modifiées et leurs utilisations
WO2025147583A1 (fr) * 2024-01-05 2025-07-10 Sail Biomedicines, Inc. Ligands pd-1 modifiés
WO2025174637A1 (fr) * 2024-02-15 2025-08-21 The Trustees Of Indiana University Procédés de détection et utilisations de pd-l1
CN120290490A (zh) * 2025-06-06 2025-07-11 山东省第二人民医院(山东省耳鼻喉医院、山东省耳鼻喉研究所) 过表达cd24的工程化外泌体递药系统及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
DE3684446D1 (de) 1985-12-28 1992-04-23 Sumitomo Pharma Arzneimittel mit verzoegerter stossweiser freisetzung.
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
SG11201508433TA (en) * 2013-04-12 2015-11-27 Andaloussi Samir El Therapeutic delivery vesicles
IL297460A (en) * 2015-06-30 2022-12-01 Nanotics Llc Compositions and methods related to absorbent particles
US11090385B2 (en) * 2015-12-21 2021-08-17 Gholam A. Peyman Early cancer detection and enhanced immunotherapy
WO2017122095A1 (fr) * 2016-01-15 2017-07-20 Orbsen Therapeutics Limited Compositions d'exosomes à base de sdc2 et leurs procédés d'isolement et d'utilisation
WO2017176762A1 (fr) * 2016-04-06 2017-10-12 Nanotics, Llc Particules comprenant des sous-particules ou des échafaudages d'acide nucléique
GB201609216D0 (en) * 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
WO2018075825A1 (fr) 2016-10-19 2018-04-26 Northwestern University Diagnostics basés sur les vésicules extracellulaires et exosomes modifiés pour une thérapie ciblée contre le cancer
IL299915A (en) * 2017-01-04 2023-03-01 Nanotics Llc Methods for assembling cleaning particles
WO2018208670A1 (fr) * 2017-05-08 2018-11-15 Trustees Of Tufts College VÉSICULES EXTRACELLULAIRES COMPRENANT UN TGF-β ATTACHÉ À LA MEMBRANE, COMPOSITIONS ET MÉTHODES D'UTILISATION ASSOCIÉES
TWI704923B (zh) * 2017-06-26 2020-09-21 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 包含胞外囊泡之製劑、用以製備該製劑之方法及其用途
US11938219B2 (en) * 2017-07-29 2024-03-26 University Of Southern California Synthetic extracellular vesicles for novel therapies
GB201717446D0 (en) * 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
GB201718681D0 (en) * 2017-11-13 2017-12-27 Evox Therapeutics Ltd Protein engineered extracellular vesicles
CN108103026B (zh) * 2017-12-05 2020-12-22 四川省肿瘤医院 用于肿瘤免疫治疗的γδ-T细胞外泌体及其制备方法
EP3986429A4 (fr) 2019-06-21 2023-07-19 Entelexo Biotherapeutics Inc. Plateformes, compositions et méthodes d'administration de composés thérapeutiques
JP7843702B2 (ja) 2019-11-28 2026-04-10 マックマスター、ユニバーシティー 細胞外小胞をプログラムするための組換えポリペプチド
WO2022133301A1 (fr) 2020-12-18 2022-06-23 Entelexo Biotherapeutics, Inc. Plateformes, compositions et méthodes pour administration thérapeutique

Also Published As

Publication number Publication date
AU2020298314A1 (en) 2022-02-03
CN114269360A (zh) 2022-04-01
US11851470B2 (en) 2023-12-26
US20220112264A1 (en) 2022-04-14
JP2022537807A (ja) 2022-08-30
EP3986429A4 (fr) 2023-07-19
US20220389078A1 (en) 2022-12-08
CA3144267A1 (fr) 2020-12-24
IL289114A (en) 2022-02-01
US20260109752A1 (en) 2026-04-23
EP3986429A1 (fr) 2022-04-27
JP2025174969A (ja) 2025-11-28
WO2020257710A1 (fr) 2020-12-24

Similar Documents

Publication Publication Date Title
EP3840730A4 (fr) Compositions pour l'administration d'agents thérapeutiques et leurs méthodes d'utilisation et leurs procédés de préparation
EP3813853A4 (fr) Compositions pour l'administration de médicaments et leurs méthodes d'utilisation
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
PH12020550341A1 (en) Niraparib formulations
EP3310343A4 (fr) Compositions implantables pour administration de médicaments et méthodes d'utilisation desdites compositions
EP3857228A4 (fr) Composés, compositions et méthodes d'amélioration de dosages
EP3921420A4 (fr) Compositions d'administration de médicament pour l'administration oculaire d'agents thérapeutiques et leurs méthodes d'utilisation
EP3256149A4 (fr) Formulations pour administration orale d'agents actifs
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
EP4297784A4 (fr) Compositions et méthodes d'administration thérapeutique
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
EP3402480A4 (fr) Compositions et méthodes d'administration par intraveineuse de 2-bromo-1-(3,3-dinitroazétidine-1-yl)éthanone
MX2020007731A (es) Compuestos moduladores de receptor de estrogeno.
EP4028059A4 (fr) Compositions médicinales stables de cannabidiol
EP3917528A4 (fr) Administration ciblée de phlip® de composés cytotoxiques puissants
EP3917971A4 (fr) Administration intracellulaire médiée par phlip® de composés immunostimulateurs
MX392259B (es) ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5a
EP3917910A4 (fr) Composés et compositions thérapeutiques
EP3908251A4 (fr) Compositions d'administration de produits pharmaceutiques et utilisations correspondantes
EP3713569A4 (fr) Compositions et méthodes d'administration d'une composition inhibitrice d'yap1/wwrt1 et d'une composition inhibitrice de gls1
MA52200A (fr) Compositions de vaa, procédés de préparation et méthodes d'utilisation
EP4419131A4 (fr) Administration orale d'agents thérapeutiques
EP3946277A4 (fr) Compositions pharmaceutiques orodispersibles d'apixaban
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
EP3982942A4 (fr) Procédés et compositions d'administration de médicament